On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis - PubMed (original) (raw)
Review
. 2000 Jun;163(2):495-529.
doi: 10.1006/exnr.2000.7397.
Affiliations
- PMID: 10833325
- DOI: 10.1006/exnr.2000.7397
Review
On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis
R T Bartus. Exp Neurol. 2000 Jun.
Abstract
Life's Journey If life is indeed a journey, then poetry must be the map that reveals all its topographic possibilitiesellipsis while science is the compass that keeps us from getting lost. -R. T. Bartus, Simple Words for Complex Lives, (c) 1998 In the nearly 20 years since the cholinergic hypothesis was initially formulated, significant progress has been achieved. Initial palliative treatments for Alzheimer's disease (AD) have proven beneficial and have gained FDA approval, the use of animal models for studying AD and other neurodegenerative diseases has achieved wider acceptance, and important insight into the potential causes and pathogenic variables associated with various neurodegenerative diseases continues to increase. This paper reviews the current status of the cholinergic hypothesis in the context of continuing efforts to improve upon existing treatments for AD and explores the role that animal models might continue to play. Using the benefit of hindsight, particular emphasis is placed on an analysis of the approaches, strategies, and assumptions regarding animal models that proved useful in developing the initial treatments and those that did not. Additionally, contemporary issues of AD are discussed within the context of the cholinergic hypothesis, with particular attention given to how they may impact the further refinement of animal models, and the development of even more effective treatments. Finally, arguments are presented that, despite the deserved enthusiasm and optimism for identifying means of halting the pathogenesis of AD, a clear need for more effective palliative treatments will continue, long after successful pathogenic treatments are available. This review, therefore, focuses on issues and experiences intended to: (a) facilitate further development and use of animal models for AD and other neurodegenerative diseases, and (b) accelerate the identification of newer, even more effective treatments.
Copyright 2000 Academic Press.
Similar articles
- Prospects for antiapoptotic drug therapy of neurodegenerative diseases.
Waldmeier PC. Waldmeier PC. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):303-21. doi: 10.1016/S0278-5846(03)00025-3. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 12657369 Review. - [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
Chabrier PE. Chabrier PE. Ann Pharm Fr. 2009 Mar;67(2):97-103. doi: 10.1016/j.pharma.2008.11.002. Epub 2009 Feb 4. Ann Pharm Fr. 2009. PMID: 19298893 Review. French. - Can herbs provide a new generation of drugs for treating Alzheimer's disease?
Anekonda TS, Reddy PH. Anekonda TS, et al. Brain Res Brain Res Rev. 2005 Dec 15;50(2):361-76. doi: 10.1016/j.brainresrev.2005.09.001. Epub 2005 Nov 2. Brain Res Brain Res Rev. 2005. PMID: 16263176 Review. - Cholinergic therapies for Alzheimer's disease: progress and prospects.
Palmer AM. Palmer AM. Curr Opin Investig Drugs. 2003 Jul;4(7):820-5. Curr Opin Investig Drugs. 2003. PMID: 14619403 Review. - The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
Terry AV Jr, Buccafusco JJ. Terry AV Jr, et al. J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. doi: 10.1124/jpet.102.041616. Epub 2003 Jun 12. J Pharmacol Exp Ther. 2003. PMID: 12805474 Review.
Cited by
- Exploring the Mechanisms and Therapeutic Approaches of Mitochondrial Dysfunction in Alzheimer's Disease: An Educational Literature Review.
Moawad MHED, Serag I, Alkhawaldeh IM, Abbas A, Sharaf A, Alsalah S, Sadeq MA, Shalaby MMM, Hefnawy MT, Abouzid M, Meshref M. Moawad MHED, et al. Mol Neurobiol. 2024 Sep 10. doi: 10.1007/s12035-024-04468-y. Online ahead of print. Mol Neurobiol. 2024. PMID: 39254911 Review. - Unveiling the therapeutic potential of Lobaria extract and its depsides/depsidones in combatting A_β_42 peptides aggregation and neurotoxicity in Alzheimer's disease.
Yang M, Yan C, Ospondpant D, Wang L, Lin S, Tang WL, Dong TT, Tong P, Xu Q, Tsim KWK. Yang M, et al. Front Pharmacol. 2024 Aug 13;15:1426569. doi: 10.3389/fphar.2024.1426569. eCollection 2024. Front Pharmacol. 2024. PMID: 39193345 Free PMC article. - Advances in Blood Biomarkers for Alzheimer's Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis.
Zhang Y, Bi K, Zhou L, Wang J, Huang L, Sun Y, Peng G, Wu W. Zhang Y, et al. Degener Neurol Neuromuscul Dis. 2024 Jul 30;14:85-102. doi: 10.2147/DNND.S471174. eCollection 2024. Degener Neurol Neuromuscul Dis. 2024. PMID: 39100640 Free PMC article. Review. - Diagnostic performance of light reflex pupillometry in Alzheimer's disease.
Gramkow MH, Clemmensen FK, Sjælland NS, Waldemar G, Hasselbalch SG, Frederiksen KS. Gramkow MH, et al. Alzheimers Dement (Amst). 2024 Jul 31;16(3):e12628. doi: 10.1002/dad2.12628. eCollection 2024 Jul-Sep. Alzheimers Dement (Amst). 2024. PMID: 39086497 Free PMC article. - Peripheral inflammation as a potential mechanism and preventive strategy for perioperative neurocognitive disorder under general anesthesia and surgery.
Li Y, Li YJ, Fang X, Chen DQ, Yu WQ, Zhu ZQ. Li Y, et al. Front Cell Neurosci. 2024 Jul 3;18:1365448. doi: 10.3389/fncel.2024.1365448. eCollection 2024. Front Cell Neurosci. 2024. PMID: 39022312 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical